Exciting News!On the 14 April 2019 it was widely reportedthat...

Exciting News!

On the 14 April 2019 it was widely reportedthat Janssen's canagliflozin drug significantly reduces the risk of renalfailure in patients with type 2 diabetes and chronic kidney disease in a phase3 clinical study. In announcing the results, Janssen stated that canagliflozinis the only medicine in nearly 20 years, and the first diabetes medicine, todemonstrate significant reduction in risk of renal failure, dialysis or kidneytransplantation. These new findings emphasise the potential of thiscollaboration to establish PromarkerD as a Complementary Diagnostic (CDx) testfor the therapeutic treatment of diabetes complications. If successful, the PromarkerD test could be used everytime Janssen diabetes drug, or the several other drugs in the gliflozin class,are prescribed. The collaboration also seeks to use PromarkerD to identifyspecific target populations that will respond to these diabetes therapies.

Raritan, N.J., March 28, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnsonannounced today the submission of a supplemental New Drug Application (sNDA) tothe U.S. Food and Drug Administration (FDA) seeking a new indication forINVOKANA^® (canagliflozin) to reducethe risk of end-stage kidney disease (ESKD), the doubling of serum creatinine,which is a key predictor of ESKD, and renal or cardiovascular (CV) death inadults with type 2 diabetes (T2D) and chronic kidney disease (CKD). Thesubmission is based on results from the Phase 3 CREDENCE (Canagliflozinand Renal Events in Diabetes with Established Nephropathy Clinical Evaluation)study, which evaluated the efficacy and safety of INVOKANA^® versus placebo inthis high-risk patient population when used in addition to standard of care.